Trillium Therapeutics Inc.

(NASDAQ: TRIL) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

Contact Information

Website: www.trilliumtherapeutics.com
Email: jwong@bplifesciences.com
Main Phone: +1 416 595-0627
Address: 100 CambridgePark Drive
Address 2: Suite 510
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02140

Issuer Information

Exchange: NSC
CEO: Jan Skvarka
Employees: 33
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A